A new era in lymphoma therapy began in 2023 when AbbVie and Genmab’s EPKINLY/TEPKINLY became the first CD20xCD3 bispecific antibody approved in the US for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). This groundbreaking approval marked a major milestone in immunotherapy, offering a novel, off-the-shelf alternative to CAR-T therapy. Just a month later, Roche’s COLUMVI entered the scene, intensifying the competition. Unlike CAR-T therapies, both EPKINLY and COLUMVI are fixed-dose, subcutaneous treatments designed to be more accessible and scalable, poised to serve a broader patient population in the R/R DLBCL space. As th...
